AYTU BIOPHARMA, INC Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)
AYTU BIOPHARMA, INC (AYTU) reported Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) of $2.60 million for the 9-month period ending 2023-03-31, per its 10-Q filed 2023-05-11.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill · last filed 2023-05-11
- AYTU BIOPHARMA, INC impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2022-12-31 was $2.60M.
- AYTU BIOPHARMA, INC impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2022-09-30 was $0.00.
- AYTU BIOPHARMA, INC impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2020-09-30 was $0.00.
- AYTU BIOPHARMA, INC impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2019 was $0.00.
| Period end | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 3 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 6 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 9 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 12 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 12 month as first filed |
|---|---|---|---|---|---|
| 2023-03-31 | $2.60M 10-Q · filed 2023-05-11 | ||||
| 2022-12-31 | $2.60M 10-Q · filed 2023-02-21 | $2.60M derived: sum of 2 quarters · filed 2023-02-21 | |||
| 2022-09-30 | $0.00 10-Q/A · filed 2023-02-21 | ||||
| 2020-09-30 | $0.00 10-Q · filed 2020-11-12 | ||||
| 2020-06-30 | $195.00K 10-Q · filed 2020-11-12 | $195.28K 10-K · filed 2020-10-06 | |||
| 2019-06-30 | $0.00 10-K · filed 2020-10-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |